We thank Huixun Jia and Xiaodong Sun for their perspective on our study.1 The goals of this first-in-human trial were to identify safe doses of RGX-314 and an optimised protocol for advanced studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback